Tris Pharma to Present Data on Cebranopadol at AAPM PainConnect Meeting
Tris Pharma, Inc., a biopharmaceutical company focused on commercial-stage development, has announced its participation in the upcoming 2025 American Academy of Pain Medicine (AAPM) PainConnect annual meeting. The conference will take place from April 3-6, 2025, in Austin, Texas, and will feature multiple presentations from Tris Pharma highlighting the company’s research and progress in pain management.
At the meeting, Tris Pharma will present new data on the burden of acute pain through an accepted poster presentation. In addition, the company will host a symposium dedicated to exploring dual-NMR agonism, a groundbreaking mechanism in pain treatment. This innovative approach is aimed at addressing moderate-to-severe pain as effectively as opioids, but with significantly lower risks of abuse, addiction, and overdose. Before the conference, Tris Pharma will also participate in a roundtable event with the American Chronic Pain Association (ACPA) focused on post-surgical pain management.
Ketan Mehta, founder and CEO of Tris Pharma, emphasized the importance of these efforts: “As we work to bring cebranopadol to patients suffering from moderate-to-severe pain, we are committed to working closely with clinicians and patients to realize the full potential of dual-NMR agonists in transforming pain management. We must also better understand the burden of acute pain when it is not effectively treated.
The data we are presenting highlight the existing treatment gaps in acute pain and show that patients and healthcare providers are forced to choose between inadequate pain relief or the use of opioids—both of which carry significant risks. These findings will provide the pain community with valuable insights into the importance of treating acute pain while highlighting the critical unmet medical need that cebranopadol can address.”
Tris Pharma Presentations at AAPM
Poster Presentation: Burden of Acute Pain in the U.S.
- Presenter: Jim Potenziano, Ph.D., Vice President of Medical Science and Information at Tris Pharma
- Date/Time: To be announced
- Location: To be announced
This poster presentation will explore the significant burden that acute pain places on patients in the U.S. Each year, millions of people experience acute pain due to injury, surgery, illness, or trauma. For many of these patients, the pain lasts for several months and often requires strong analgesics like opioids to manage. Tris Pharma’s presentation will underline the gaps in effective treatment options for acute pain and the growing need for safer alternatives.
Symposium on Dual-NMR Agonism: A New Approach to Pain Treatment
Tris Pharma will also host a symposium that focuses on dual-NMR agonism, a novel mechanism for treating pain. This mechanism has the potential to treat moderate-to-severe pain similarly to opioids but with a significantly reduced risk of abuse, addiction, and overdose.
- Symposium Title: Break the Mold in Pain Biology: The Promise of a New Mechanism that May Overcome the Shortfalls of Current Moderate-to-Severe Pain Medications
- Presenters:
- Lawrence Toll, Ph.D., Florida Atlantic University
- Jeffrey Gudin, M.D., University of Miami Miller School of Medicine
- Location: Salon F, Fourth Floor
- Date and Time: April 3, 12:00 – 1:00 p.m. CT
The symposium will be led by scientists who have extensive experience in the research and development of novel pain therapies. Their presentations will shed light on how dual-NMR agonism could overcome the limitations of existing pain medications, particularly for patients with moderate-to-severe pain.
Roundtable Event with the ACPA
In addition to the poster presentation and symposium, Tris Pharma will participate in a roundtable discussion with the American Chronic Pain Association (ACPA). Titled “Bridging Perspectives: A Comprehensive Roundtable on Post-Surgical Pain Management,” this event will bring together clinicians, researchers, and patients to discuss the latest research on treating post-surgical pain. They will explore best practices for managing pain after surgery, current challenges, and promising new therapies that could help alleviate pain while reducing reliance on opioids.
Tris Pharma at PainConnect
At the PainConnect conference, Tris Pharma will also have a booth where executives from the company will be available to provide more information on the findings presented at the congress. The booth will be located at Spot D, and attendees can visit to learn more about Tris Pharma’s latest developments and the potential of cebranopadol.
About Acute Pain
Acute pain is a common condition that affects millions of individuals each year, resulting from various causes such as injury, surgery, illness, trauma, burns, or painful medical procedures. Typically, acute pain lasts up to three months and resolves once the underlying cause is treated or healed. For moderate-to-severe acute pain, opioid analgesics such as oxycodone are often necessary, especially after joint replacements, orthopedic surgeries, and major traumas. However, opioids carry significant risks of addiction, abuse, and overdose, making it critical to explore new, safer alternatives for pain management.
Tris Pharma’s cebranopadol, which works through a dual-NMR agonist mechanism, is a promising treatment option that aims to address these risks while effectively managing pain. As part of its ongoing commitment to advancing pain management, Tris Pharma is focused on developing innovative therapies to meet the significant unmet needs in the treatment of acute and chronic pain.
